Understanding Most Bothersome Symptom Relief in Migraine Treatment Studies

Most bothersome symptom (MBS) freedom is an important endpoint in clinical trials for acute migraine treatments. This measure allows patients to identify their single most troubling symptom beyond headache pain—such as nausea, light sensitivity, or sound sensitivity—and tracks whether that specific symptom resolves after treatment. The FDA recognizes MBS freedom as a meaningful outcome because it reflects what matters most to individual patients during a migraine attack.

In Ubrelvy's pivotal clinical trials, patients achieved statistically significant MBS freedom compared to placebo at 2 hours post-dose. The trials measured freedom from the patient's self-identified most bothersome symptom, with common symptoms including photophobia, phonophobia, and nausea. These results demonstrated Ubrelvy's ability to address the full spectrum of migraine symptoms that impact patients' daily functioning.

Direct comparisons between different migraine medications using MBS data can be challenging due to variations in study design, patient populations, and trial methodologies. Each clinical trial program uses specific inclusion criteria, dosing regimens, and measurement timepoints that may differ across studies. While both Ubrelvy and other acute migraine treatments have shown efficacy in their respective trials, healthcare providers consider multiple factors including individual patient characteristics, medical history, and treatment response when selecting the most appropriate therapy.

Patients experiencing migraine should work closely with their healthcare providers to evaluate treatment options based on their specific symptom profile and treatment goals. Understanding how clinical trial endpoints like MBS freedom are measured can help inform discussions about which acute migraine treatment may be most suitable for individual needs.